PRKAR1A inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10603-10612

  Robinson White, Audrey J ^a   Leitner, Wolfgang W ^b   Aleem, Eiman ^c   Kaldis, Philipp ^c   Bossis, Ioannis ^a   Stratakis, Constantine A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; B RAF KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PRKAR1A GENE; PROTEIN PHOSPHORYLATION;

APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; ISOPROTERENOL; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 33751301602     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2200     Document Type: Article

References (50)

1. Carney JA, Young WF. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 1992;2:6-21.
2. Stratakis CA, Papageorgiou T, Premkumar A, et al. Ovarian lesions in Carney complex: clinical genetics and possible predisposition to malignancy. J Clin Endocrinol Metab 2000;85:4359-66.
3. Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997;82:2037-43.
4. Stratakis CA. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit (PRKAR1A) in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas" (Carney complex). Ann N Y Acad Sci 2002;968:3-21.
5. Kirschner LS, Sandrini F, Monbo J, Li JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037-46.
6. Kirschner LS, Carney JA, Pack S, et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
7. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 2004;11:265-80.
8. Griffin KJ, Kirschner LS, Matyakhina L, et al. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res 2004;64:8811-5.
9. Griffin KJ, Kirschner LS, Matyakhina L, et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumors: comparison with Carney complex and other PRKAR1A-induced lesions. J Med Genet 2004;41:923-31.
10. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex-tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005;65:4506-14.
11. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004;84:137-67.
12. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther 1991;50:123-45.
13. Robinson-White A, Hundley TR, Shiferaw M, Bertherat J, Sandrini F, Stratakis CA. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 2003;12:1475-84.
14. Harada H, Becknell B, Wilm M, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 1999;3:413-22.
15. Robinson-White A, Stratakis CA. Protein kinase A signaling: "cross-talk" with other pathways in endocrine cells. Ann N Y Acad Sci 2002;968:256-70.
16. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999;11:211-8.
17. Vossler MR, Yao H, York RD, Pan M-G, Rim CS, Stork PJS. cAMP activates MAP kinase and Elk-1 through a B-raf and Rap1-dependent pathway. Cell 1997;89:73-82.
18. Dan CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
19. Chang F, Steelman LS, Shelton JG, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 2003;22:469-80.
20. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001;92:57-70.
21. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
22. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
23. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int J Oncol 2003;22:15-20.
24. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the Trail (APO-2L) apoptosis systems. Exp Cell Res 2000;256:58-66.
25. Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A. Control of apoptosis by APO2 ligand. Recent Prog Horm Res 1999;54:225-34.
26. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo H-M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein BAD. Cancer Res 2003;63:8330-7.
27. Holmstrom TH, Schmitz I, Soderstrom TS, et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J 2000;19:5418-28.
28. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
29. Homburg CH, de Hass M, von dem Borne AE, Verhoeven AJ, Reutelingsperger CP, Roos D. Human neutrophils lose their surface Fc γ RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood 1995;85:532-40.
30. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003;13:1775-85.
31. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University; 1968.
32. Eberhart SA, Russell WA. Stability parameters for comparing varieties. Crop Sci 1966;6:36-40.
33. Satoh M, Yasuda T, Higaki T, et al. Innate apoptosis of human B lymphoblasts transformed by Epstein-Barr virus: modulation by cellular immortalization and senescence. Cell Struct Funct 2003;28:61-70.
34. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 2005;3: e404.
35. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W. Cyclic AMP-dependent protein kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 2002;22:3237-46.
36. Amieux PS, Cummings DE, Motamed K, et al. Compensatory regulation of RIα protein levels in protein kinase A mutant mice. J Biol Chem 1997;272:3993-8.
37. Staples KJ, Bergmann M, Tomita K, et al. Adenosine 3′,5′- cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001;167:2074-80.
38. Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998;282:2275-9.
39. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
40. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36:165-75.
41. MAPK pathway. J Biol Chem 1996;271:20608-16.
42. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002;1:103-10.
43. Nadella KS, Kirschner LS. Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res 2005;65:10307-15.
44. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
45. Stepczynska A, Lauber K, Engels IH, et al. Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene 2001;20:1193-202.
46. Plumas J, Jacob M-C, Chaperot L, Molens J-P, Sotto J-J, Bensa J-C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/APO-1)-mediated apoptosis. Blood 1998;91:2875-85.
47. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003;15:983-92.
48. Fulda S, Debatin K-M. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 2004;1705:27-41.
49. Moynagh PN. The NF-κB pathway. J Cell Sci 2005;118:4589-92.
50. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 2004;1028:150-6.